The arrival of a 750mcg teriparatide injection in Australia has been somewhat restricted , with distribution primarily through specialist physicians and designated treatment centers. Early market uptake for this concentrated formulation remain undisclosed from the supplier , although experts suggest gradual adoption rates . Availability to patients